Almost there...

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox.

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

Report Company Directory

ONCOVISTA INNOVATIVE THERAPIES INC

ONCOZENGE

Oncternal Therapeutics Inc

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC by GlobeNewsWire
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer by GlobeNewsWire
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives by GlobeNewsWire
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results by GlobeNewsWire
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results by GlobeNewsWire
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer by GlobeNewsWire
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit by GlobeNewsWire
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer by GlobeNewsWire
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results by GlobeNewsWire
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results by GlobeNewsWire

ONDARRETA ZURRIOLA DE INVERSIONES

Ondas Holdings

InsiderInsights Weekly Report: March 9, 2024 by InsiderInsights.com
InsiderInsights Weekly Report: March 2, 2024 by InsiderInsights.com
InsiderInsights.com Daily Ratings Report: February 28, 2024 by InsiderInsights.com
InsiderInsights Weekly Report: December 2, 2023 by InsiderInsights.com
InsiderInsights Weekly Report: November 25, 2023 by InsiderInsights.com
InsiderInsights.com Daily Ratings Report: November 24, 2023 by InsiderInsights.com
InsiderInsights Weekly Report: January 7, 2023 by InsiderInsights.com
Ondas Holdings Inc. Announces $30,000,000 Follow-On Public Offering by BusinessWire
InsiderInsights Weekly Report: December 31, 2022 by InsiderInsights.com
InsiderInsights Daily Ratings Report: December 27, 2022 by InsiderInsights.com

ONDINE BIOMEDICAL INC.

Hybridan Research: Sector Piece: Undervalued, Under Researched Small Caps by Hybridan
Hybridan Small Cap Feast: 12/06/2025 by Hybridan
Hybridan Small Cap Feast: 05/06/2025 by Hybridan
Hybridan Small Cap Feast: 15/05/2025 by Hybridan
Hybridan Monthly 1 May 2025 by Hybridan
Friday Take Away: 11 April 2025 by Hybridan
Hybridan Small Cap Feast: 09/04/2025 by Hybridan
Hybridan Small Cap Feast: 19/02/2025 by Hybridan
Ondine Biomedical - Steriwave initiates UK pilot study with NHS by Edison Investment Research
Ondine Biomedical - Proprietary platform testing standard of care by Edison Investment Research

Ondine Biomedical Inc.

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Report Company Directory

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe